These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 8804744)
1. Fostering partnerships for vaccine development: a delicate fabric. Douglas RG Bull N Y Acad Med; 1996; 73(1):113-23. PubMed ID: 8804744 [No Abstract] [Full Text] [Related]
2. The benefits and threats of research partnerships with industry. Duval G Crit Care; 2005 Aug; 9(4):309-10. PubMed ID: 16137365 [No Abstract] [Full Text] [Related]
7. Vaccine partnerships to tackle neglected diseases. Hughes B Nat Rev Drug Discov; 2008 Apr; 7(4):277-8. PubMed ID: 18396477 [No Abstract] [Full Text] [Related]
8. Drug and vaccine development for infectious diseases: the value of priority review vouchers. Matheny J; Smith B; Courtney B; Mair M Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907 [No Abstract] [Full Text] [Related]
9. United States vaccine research: a delicate fabric of public and private collaboration. Marcuse EK Pediatrics; 1998 Oct; 102(4 Pt 1):1002-3. PubMed ID: 9786767 [No Abstract] [Full Text] [Related]
10. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Vitiello B; Heiligenstein JH; Riddle MA; Greenhill LL; Fegert JM Biol Psychiatry; 2004 Jul; 56(1):3-9. PubMed ID: 15219466 [TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical sciences in 2020. Crommelin D; Stolk P; Besançon L; Shah V; Midha K; Leufkens H Nat Rev Drug Discov; 2010 Feb; 9(2):99-100. PubMed ID: 20118959 [No Abstract] [Full Text] [Related]
12. New technology, old struggles plague vaccine developers. Phillips L Hosp Technol Ser; 1994 Oct; 13(13):3-6. PubMed ID: 10137963 [No Abstract] [Full Text] [Related]
14. The role of US government agencies in vaccine research and development. Folkers GK; Fauci AS Nat Med; 1998 May; 4(5 Suppl):491-4. PubMed ID: 9585193 [No Abstract] [Full Text] [Related]
15. Comparative effectiveness casts first shadows across US industry. Waltz E Nat Biotechnol; 2009 Mar; 27(3):211-2. PubMed ID: 19270651 [No Abstract] [Full Text] [Related]
17. Vaccine and microbicide tax credit legislation introduced in Congress. AIDS Treat News; 1999 Apr; (No 316):7-8. PubMed ID: 11366301 [TBL] [Abstract][Full Text] [Related]
18. Cooperative agreement for Applied Research on Surveillance of Vaccine Preventable Diseases in Managed Care Settings; notice of availability of funds. Centers for Disease Control and Prevention. Fed Regist; 1999 May; 64(93):26419-21. PubMed ID: 10558533 [No Abstract] [Full Text] [Related]
19. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development. Kesselheim AS Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908 [No Abstract] [Full Text] [Related]
20. The winning shot. New vaccine technologies to offer pinpoint attacks on a variety of potentially deadly diseases. Kirchheimer B Mod Healthc; 2005 Nov; 35(46):52-4. PubMed ID: 16334833 [No Abstract] [Full Text] [Related] [Next] [New Search]